| Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I. | |
| | |
MedLine Citation:
|
PMID: 9444886 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Left ventricular hypertrophy (LVH) is a generalized adaptation to altered myocardial load. Hypertension induces significant increases in ventricular IGF-I gene expression that occur coordinately with development of LVH. To test whether IGF-I promotes initiation of LVH, we examined ventricular IGF-I mRNA content in spontaneously hypertensive rats (SHRs) treated with antihypertensive drugs that limit or permit LVH. METHODS: Prehypertensive SHRs were left untreated or treated with enalapril, nifedipine, or hydralazine. Systolic blood pressure (SBP), hypertrophy index (ventricular weight/body weight), and ventricular IGF-I mRNA levels were examined 2, 4, and 6 weeks after beginning therapy in the experimental groups. RESULTS: Systolic blood pressure reached hypertensive levels after 2 weeks in untreated animals, and was controlled in the treated animals. The hypertrophy index in untreated animals was significantly elevated at 4 weeks. By 6 weeks, the hypertrophy indices of both the enalapril- and nifedipine-treated groups were significantly lower than that of the untreated group. In contrast, the hypertrophy index of the hydralazine-treated animals remained comparable to that of the untreated animals. By 4 weeks, IGF-I mRNA levels in the enalapril- and nifedipine-treated groups were significantly lower than those in the untreated and hydralazine-treated groups. CONCLUSIONS: We conclude that: (1) antihypertensive drugs that reduce LVH blunt ventricular IGF-I mRNA content; and (2) the hemodynamic effects of antihypertensives may be dissociated from their ability to promote or limit a hypertrophic response. The clear association of LVH with ventricular IGF-I mRNA content suggests that IGF-I is an important determinant of ventricular growth. Our data also suggest that angiotensin-converting enzyme inhibitors and calcium channel blockers may reduce LVH by inhibiting cardiac IGF-I gene expression. |
| | |
Authors:
|
T J Donohue; L D Dworkin; J Ma; M N Lango; V M Catanese |
Related Documents
:
|
3623686 - Echocardiographic left ventricular mass and function in the hypertensive baboon. 2946286 - Hemodynamics and left ventricular function: a comparison between adult racing greyhound... 11339786 - Electroconvulsive therapy impairs systolic performance of the left ventricle. 2525526 - Impaired left ventricular functional reserve in hypertensive patients with left ventric... 17454406 - World-smallest lvad with 27 g weight, 21 mm od and 5 l min-1 flow with 50 mmhg pressure... 9093006 - An analysis of arterial disease mortality and bupa health screening data in men, in rel... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of investigative medicine : the official publication of the American Federation for Clinical Research Volume: 45 ISSN: 1081-5589 ISO Abbreviation: J. Investig. Med. Publication Date: 1997 Dec |
Date Detail:
|
Created Date: 1998-02-12 Completed Date: 1998-02-12 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9501229 Medline TA: J Investig Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 584-91 Citation Subset: IM |
Affiliation:
|
Division of Molecular Endocrinology, New York University School of Medicine, New York 10016, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / therapeutic use* Blood Pressure / drug effects Enalapril / therapeutic use Heart / drug effects* Hydralazine / therapeutic use Hypertension / drug therapy* Hypertrophy, Left Ventricular / metabolism, prevention & control* Insulin-Like Growth Factor I / metabolism* Male Myocardium / metabolism*, pathology Nifedipine / therapeutic use Organ Size / drug effects RNA, Messenger / biosynthesis, drug effects Rats Rats, Inbred SHR |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/RNA, Messenger; 21829-25-4/Nifedipine; 67763-96-6/Insulin-Like Growth Factor I; 75847-73-3/Enalapril; 86-54-4/Hydralazine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hyperoxia and glutathione depletion in the isolated perfused rat liver.
Next Document: Consultation-liaison in child psychiatry: a review of the past 10 years. Part I: Clinical findings.